scholarly article | Q13442814 |
P2093 | author name string | M Needham | |
R A Stockley | |||
P433 | issue | 6 | |
P304 | page(s) | 992-1000 | |
P577 | publication date | 2005-06-01 | |
P1433 | published in | European Respiratory Journal | Q12257435 |
P1476 | title | Exacerbations in {alpha}1-antitrypsin deficiency | |
P478 | volume | 25 |
Q38092905 | Airway disease in alpha-1 antitrypsin deficiency |
Q39450745 | Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life |
Q64974062 | Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients. |
Q38092880 | Alpha-1 antitrypsin deficiency: the European experience |
Q37986292 | Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent |
Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
Q40980393 | Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT): The United Kingdom Registry |
Q28392320 | Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach |
Q37362591 | Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency |
Q91671206 | Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNet's Disease Management Program |
Q64986349 | Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency. |
Q33713789 | Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry. |
Q37780552 | Emerging drugs for alpha-1-antitrypsin deficiency |
Q57175296 | Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? |
Q46303528 | Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment |
Q33743024 | Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence |
Q36275067 | Patterns and characterization of COPD exacerbations using real-time data collection |
Q23911017 | Rationale and design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis. Alpha-1 protocol |
Q36444197 | Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD. |
Q51073341 | Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease strategy to clinically relevant outcomes in individuals with α1-antitrypsin deficiency. |
Q36379352 | Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease |
Q37303247 | Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. |
Q37362027 | The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis |
Q47703811 | Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy |
Q48076378 | Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency |
Q83079365 | [Augmentation therapy with alpha-1 antitrypsin: 20 year- follow-up of a deficient patient] |
Search more.